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Abstract 
Use of biofilm-dispersing NO-donor compounds in combination with antibiotics has emerged 
as a promising new strategy for treating drug-resistant bacterial biofilm infections. This paper 
details the synthesis and preliminary evaluation of six cephalosporin-3′-diazeniumdiolates as 
biofilm-targeted NO-donor prodrugs. Each of the compounds is shown to release NO 
following reaction with the bacteria-specific enzyme β-lactamase and to trigger dispersion of 
Pseudomonas aeruginosa biofilms in vitro.  
 
The discovery of clinically useful therapeutics and novel treatment strategies against bacterial 
biofilm infections is one of the greatest challenges in modern infectious disease control.1 In 
2006 we reported that low concentrations of the biologically ubiquitous gas nitric oxide (NO) 
trigger biofilm dispersion in the important human pathogen Pseudomonas aeruginosa and 
demonstrated that the spontaneous NO-donor sodium nitroprusside (SNP) greatly enhances 
the efficacy of antibacterial compounds (e.g. tobramycin) in the removal of P. aeruginosa 
biofilms.2 Follow-up studies showed that NO levels in the pM and low nM range mediate 
dispersal in several other single- and multi-species bacterial and yeast biofilms3 and that the 
effects correlate with increases in bacterial phosphodiesterase activity and associated 
decreases in cyclic-di-GMP levels.4 These combined results have unveiled a putative new 
anti-biofilm strategy which uses low concentrations of NO-donor compounds in combination 
with antibiotics to clear bacterial biofilm infections. 
 
 
Scheme 1. Proposed mechanism of β-lactamase-triggered NO release and biofilm dispersion 
by cephalosporin-3′-diazeniumdiolates (e.g. 1). 
 
Targeted prodrugs capable of releasing NO only after reaction with a bacteria-specific 
enzyme represent ideal NO-donors for clinical anti-biofilm applications (as opposed to 
spontaneous NO donors) since they should localise NO to biofilm infection sites and 
minimise exposure of host tissues to NO (and associated side-effects). We recently described 
a rationally designed cephalosporin-3′-diazeniumdiolate NO-donor prodrug 1 which 
selectively releases NO upon contact with the bacterial enzyme β-lactamase (proposed 
mechanism shown in Scheme 1).5 Compound 1 was shown to effect NO-dependent P. 
aeruginosa biofilm dispersal and to act synergistically with front-line antibiotics (tobramycin 
and ciprofloxacin) in clearing bacterial biofilms. This paper details synthetic efforts towards 
1 and demonstrates the versatility of the chemistry by producing five analogues carrying 
variations in the cephalosporin 7-acylamido side chain and 3′-diazeniumdiolate NO-donor 
portions. Each of the analogues is shown to release NO upon reaction with β-lactamase and 
to disperse P. aeruginosa biofilms in vitro. 
 
Alkylation of sodium diazeniumdiolate salts with ester protected 3′-chloro-cephalosporins 
appeared as a viable route towards cephalosporin-3′-diazeniumdiolates since terminal oxygen 
alkylation of sodium diazeniumdiolates with alkyl halides was well established.6 Initial 
investigations with diphenylmethyl (DPM)- or p-methoxybenzyl (PMB)-protected 3′-chloro-
cephalosporin esters 2 showed that alkylation reactions with sodium diazeniumdiolate 3 did 
not proceed. Finkelstein conversion of 2 to the corresponding allylic iodides (NaI/acetone) 
followed by purification and reaction with 3 did produce the desired alkylation products 4 
under several conditions (Electronic Supplementary Information, Scheme S1), however the 
yields were consistently low due to double bond migration and formation of inseparable 
mixtures containing the undesired ∆2-isomers 4a as the major product.7 Addition of 1.0 mol 
eq of solid 3 in situ to freshly prepared allylic iodide/acetone solutions of 2 afforded mixtures 
wherein the ∆3-isomer predominated (i.e., 4:4a = 80:20 for DPM-protected 2, 90:10 for 
PMB-protected 2).  The low solubility of 3 in acetone may have reduced solution basicity 
minimising deprotonation at the cephalosporin 2-position. It is well established that 
deprotonation here triggers double bond migration during substitution reactions with basic 
nucleophiles and cephalosporins carrying leaving groups at the 3′-position.7 
 
The optimised alkylation conditions were used to prepare two analogues of 4 carrying 
variations in the 7-acylamido side chain (R1: compounds 6, 8, Figure 1). Compound 4, 
bearing a thiophenacetyl group at R1 (as found in Cefalotin and other cephalosporins that 
have been used clinically), was obtained pure in 85% isolated yield from 2 following silica 
gel chromatography and recrystallisation from MeOH or EtOH. Compound 6, carrying a 
phenacetyl group at R1 (as found in Cephaloram), was obtained in 75% yield from 5, while 
the yield of 8 (R1 = 1-tetrazolylacetyl, as found in Cefazolin and others) was lower at 14% 
(from 7) due to appreciable formation of the ∆2-isomer 8a (42% isolated yield). 
 
It was of particular interest to explore whether diazeniumdiolate salts other than 3 (NO 
release t1/2 = 2.0 min)8 could be attached to the cephalosporin scaffold, especially those with 
similarly short NO-release half-lives. We predict that diazeniumdiolates with short half-lives 
should work best in clinical anti-biofilm applications since rapid NO release from the 
diazeniumdiolate anions following expulsion from the cephalosporin prodrug would be 
necessary to limit their diffusion away from biofilms before releasing NO. Reaction of 3′-
chloro-cephalosporin PMB ester 5 with sodium diazeniumdiolate 9 (t1/2 = 2.8 sec)8 under the 
optimised conditions afforded alkylated product 10 in 66% yield. Reactions of 5 with salts 11 
(t1/2 = 1.9 min)9 and 13 (t1/2 = 2.0 min)9 similarly produced the desired adducts 12 and 14 in 
39% and 80% yields, respectively. 
 
PMB-deprotection using neat trifluoroacetic acid/anisole at 0 ºC proceeded smoothly for all 
analogues affording the pure cephalosporin-3′-diazeniumdiolate free carboxylic acids 1, 15-
19 in 36-93% yields (Figure 1). The free acids 1, 15, 17 and 18 could be converted to their 
water soluble potassium salts (21, 20, 23 and 24, respectively) by stirring with 1.0 mol eq 
aqueous KOH at 0 ºC followed by freeze-drying. Applying the same procedure with acids 16 
and 19 led to decomposition. 
 
 
Fig. 1 Synthesis of cephalosporin-3′-diazeniumdiolates. 
 
Release of NO from cephalosporin-3′-diazeniumdiolate free acids 1, 15-19 in the presence 
of a commercial β-lactamase (penicillinase, Sigma) was studied amperometrically at pH 7 in 
100 mM Tris buffer (Figure 2). Compound 18 was found to be stable over 15 min following 
addition to buffer, as indicated by an absence of detectable NO. Compounds 1 and 17 showed 
evidence of slight decomposition producing low but detectable levels of NO, presumably 
through β-lactam hydrolysis and expulsion of the NO donor. Compounds 15, 16 and 19 
appeared to be less stable generating 2-3 fold higher levels of NO than 1 or 17 upon addition 
to buffer. Treatment with β-lactamase (0.1 U/mL) triggered immediate release of NO from 
each of the acids. Compounds 1 and 18 reached steady-state NO concentrations of ~2 µM 
within 15 min, while acids 15, 16, 17 and 19 produced higher NO levels, reaching steady-
state concentrations of ~3-4 µM over the same period. Adding a further 0.2 U/mL of β-
lactamase to each of the acids led to additional ~2-fold increases in NO and reestablishment 
of steady-state NO concentrations within 15 min. Formation of steady-state NO 
concentrations and release of NO upon addition of a second aliquot of enzyme are consistent 
with the reaction of the β-lactamase with cephalosporin-3′-diazeniumdiolates leading to 
enzyme inhibition. Quenching of the amperometric response upon addition of the free radical 
scavenger 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (PTIO) confirmed that the 
observed signals were due to NO. 
 
 
Fig. 2 Amperometric characterisation of NO release from cephalosporin-3′-diazeniumdiolate 
free acids 1, 15-19 in the presence of β-lactamase. Arrows indicate addition of the following 
to reaction vials containing 10 mL Tris buffer (100 mM) at pH 7.0:  (a) 10 µL of 100 mM 
cephalosporin-3′-diazeniumdiolate free acid, (b) 10 µL 100 U/mL β-lactamase, (c) 20 µL 100 
U/mL β-lactamase, (d) 80 µL of 10 mM free radical scavenger PTIO. 
 
Dispersion of P. aeruginosa biofilms by cephalosporin-3′-diazeniumdiolate free acids 1, 15-
19, along with the ∆2-isomer 16a, was examined in vitro using microtiter plate biofilm assays 
(Figure 3).5 Briefly, P. aeruginosa PAO1 wild type biofilms were grown in 24-well plates 
containing sub-inhibitory imipenem (0.3 µg/mL) to induce β-lactamase expression. After 6 h, 
the biofilms were treated with test compounds and incubated for 15 min before washing, 
staining with crystal violet and quantifying the remaining biofilms by measuring OD550 of 
the homogenized suspensions. Compounds 1 and 15-19 all showed dose-dependent biofilm 
dispersion responses in the range 5−100 µM. Compounds 1 and 17 appeared as the most 
potent members of the series reducing biofilm mass at 5 µM by 31% and 28%, respectively. 
The other compounds showed no significant effect at this concentration. At 10 µM, 
compound 1 reduced biofilm mass by 78%, with only slight further reductions being 
observed at higher concentrations (87% at 50 µM, 91% at 100 µM). A similar dose 
dependency was observed with 17. While less potent, the other four analogues 15, 16, 18 and 
19 all reduced biofilms by more than 70% at 100 µM. As expected, the ∆2-isomer of 16 (i.e., 
16a) showed no dispersion effect at any concentration, consistent with its inability to undergo 
the conjugate elimination reaction to expel the diazeniumdiolate anion following β-lactam 
cleavage. 
 
 
Fig. 3 Dispersal of P. aeruginosa biofilms by cephalosporin-3′-diazeniumdiolate free acids 1, 
15-19. P. aeruginosa PAO1 biofilms grown in microtiter plates were pre-treated with 
imipenem (0.3 µg/mL) before exposing to various concentrations of compounds (15 min) and 
quantifying the remaining biofilm mass by crystal violet staining and measurement of 
OD550. (n = 2) Control biofilms treated with imipenem alone produced OD550 readings of ~ 
3-3.5. 
 
Conclusions 
Bacteria encased in biofilms are known to exhibit upwards of 10−1,000-fold higher resistance 
to biocides and traditional antibiotics and to be less susceptible to host immune defences than 
their free-swimming planktonic counterparts.10 As a result, chronic bacterial infections tend 
to be biofilm-based. In our anti-biofilm strategy, low concentrations of NO-donors are used 
to first trigger biofilm dispersion such that the more vulnerable planktonic bacteria can be 
cleared by conventional antibiotics working in concert with host immune defences.2-4 It is 
important to note that NO at the concentrations used are not toxic to bacteria, but rather 
induce a genetically programmed response. The current work has advanced the strategy 
significantly towards clinical utility in describing a novel class of drug-like biofilm-targeted 
NO-donor prodrugs (i.e., cephalosporin-3′-diazeniumdiolates) that make use of the known 
tendency of cephalosporins to eject leaving groups from the 3′-position via conjugate 
elimination12 following β-lactam cleavage (in this case diazeniumdiolate NO donors). Six 
examples from the class were prepared using similar chemistry and each was shown to 
release NO upon contact with β-lactamase and to trigger biofilm dispersion in P. aeruginosa, 
an important pathogen responsible for recalcitrant and often fatal bronchopulmonary biofilm 
infections, especially in cystic fibrosis (CF) patients.11 Studies aimed at identifying optimal 
cephalosporin-3′-diazeniumdiolate development candidates for these and other types of 
biofilm-based chronic infections are on-going in our laboratories. 
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